Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in ANCA Vasculitis
NCT06590545Phase 2Not yet recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06590545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590545.